SCHEMBL24312185

SCHEMBL24312185

OC(C#Cc1cc(Cl)cc(N2CCOCC2)n1)C(F)(F)F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 2/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ RAF1 P04049 8/20 0.39
▸ PIK3CA P42336 4/20 0.39
▸ PIK3CB P42338 2/20 0.39
▸ MTOR P42345 2/20 0.39
▸ KMT2A Q03164 2/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ PIK3CD O00329 1/20 0.36
▸ PIK3C2B O00750 1/20 0.36
▸ PIK3R1 P27986 1/20 0.36
▸ AKR1C3 P42330 1/20 0.36
▸ PIK3CG P48736 1/20 0.36
▸ PRKDC P78527 1/20 0.36
▸ PIK3C3 Q8NEB9 1/20 0.36
▸ PIK3R5 Q8WYR1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24312188 0.79 MAPT (0.39) CYP1A2CYP2D6MAPTPIK3CAPIK3CB
SCHEMBL24595190 0.77 MAPT (0.47) CYP1A2CYP2D6MAPTPIK3CAKMT2A
SCHEMBL24312182 0.76 KMT2A (0.46) CYP1A2CYP2D6MAPTPIK3CAKMT2A
SCHEMBL29610649 0.74 MAPT (0.49) CYP1A2CYP2D6MAPTPIK3CAKMT2A
SCHEMBL24312193 0.74 MAPT (0.49) CYP1A2CYP2D6MAPTPIK3CAKMT2A
SCHEMBL24312231 0.74 KMT2A (0.44) CYP1A2CYP2D6MAPTPIK3CAKMT2A
SCHEMBL17204101 0.72 MAPT (0.61) CYP1A2CYP2D6MAPTPIK3CBKMT2A
SCHEMBL24312280 0.71 RAF1 (0.44) CYP1A2CYP2D6MAPTRAF1PIK3CA
SCHEMBL24312249 0.71 MAPT (0.44) CYP1A2CYP2D6MAPTRAF1PIK3CA
SCHEMBL29611284 0.71 MAPT (0.44) CYP1A2CYP2D6MAPTRAF1PIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11746095-B2 Inhibtors of RAF kinases KINNATE BIOPHARMA INC. (US) 2023-09-05 — — US disclosed
US-11746095-B2 Inhibtors of RAF kinases KINNATE BIOPHARMA INC. (US) 2023-09-05 — — US disclosed
US-11746095-B2 Inhibtors of RAF kinases KINNATE BIOPHARMA INC. (US) 2023-09-05 — — US disclosed
US-20220356160-A1 INHIBITORS OF RAF KINASES Pierre Fabre Médicament (FR) 2022-11-10 — — US disclosed
US-11377431-B2 Inhibitors of RAF kinases KINNATE BIOPHARMA INC. (US) 2022-07-05 — — US disclosed
US-11377431-B2 Inhibitors of RAF kinases KINNATE BIOPHARMA INC. (US) 2022-07-05 — — US disclosed
WO-2022081469-A1 INHIBITORS OF RAF KINASES KINNATE BIOPHARMA INC. (US) 2022-04-21 — — WO disclosed
WO-2022081469-A1 INHIBITORS OF RAF KINASES KINNATE BIOPHARMA INC. (US) 2022-04-21 — — WO disclosed
US-20220112170-A1 INHIBITORS OF RAF KINASES Pierre Fabre Médicament (FR) 2022-04-14 — — US disclosed
US-20220112170-A1 INHIBITORS OF RAF KINASES Pierre Fabre Médicament (FR) 2022-04-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220112170-A1 INHIBITORS OF RAF KINASES BRAF, RAF1, ARAF CYP1A2 4302/4885CYP2D6 4339/4885MAPT 2859/4885
US-11746095-B2 Inhibtors of RAF kinases RAF1, BRAF, ARAF CYP1A2 4124/4885CYP2D6 4554/4885MAPT 3440/4885
US-20220356160-A1 INHIBITORS OF RAF KINASES BRAF, RAF1, ARAF CYP1A2 4302/4885CYP2D6 4339/4885MAPT 2859/4885
US-11377431-B2 Inhibitors of RAF kinases BRAF, RAF1, ARAF CYP1A2 4302/4885CYP2D6 4339/4885MAPT 2859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback